NY-AQARA
27.2.2024 14:01:39 CET | Business Wire | Press release
Aqara, a leading provider of smart home solutions, is excited to initiate the crowdfunding campaign for its latest home access solution, the Smart Lock U200, on Kickstarter. Designed for flexibility, convenience and security, the U200 lock is built upon the latest Thread protocol and natively Matter-enabled, aiming for effortless integration with the widest range of smart home devices across systems and brands1.
At its core, the Aqara U200 utilizes modern engineering crafted to provide users with numerous secure access options, ranging from fingerprints, one-time and recurring PIN codes, remote access via mobile apps, voice assistant commands to Aqara NFC cards and physical keys. Aqara is also working to add the HomeKey support to the U200 lock, which allows iOS users to unlock by simply tapping a compatible iPhone and Apple Watch. The U200 will be one of the first Matter-compatible locks to support HomeKey unlocking, and the Aqara team is sparing no time on developing and testing before delivering the optimized experiences2.
The U200 features a retrofit design, allowing for hassle-free installation on existing doors - without the need for extensive modification or renovation. Compatible with most doors in both Europe and North America, it attaches to existing lock mechanisms such as European cylinders (emergency function required) and deadbolts using one of the provided adapters3. The U200 intends to bring the modern keyless lifestyle to a broad array of homeowners and renters, while preserving the option to use traditional keys. Users also enjoy easy access sharing, remote access control, and real-time lock status updates for enhanced convenience and security.
The U200 lock runs on rechargeable Li-Ion batteries, while its wireless keypad can either be powered by a pack of four AAA batteries or wired to the existing doorbell wire (12V-24V DC power supply). Thanks to the power-efficient Thread protocol, the U200 lock features a battery life of up to 6 months between each charge4. Moreover, the wireless keypad boasts an IPX5 rating and withstands extreme heat and cold (-18℃/0℉ to 66℃/151℉), ensuring endurance under any climate.
As an integral part of a connected home, the U200 smart lock seamlessly works with other smart home accessories, allowing users to create a fully automated and customized smart home experience. For example, to disarm the home security system automatically when the U200 is unlocked by a family member, or to activate the indoor camera and the video doorbell after consecutive failed attempts to unlock the door. With three color options available for pre-order on Kickstarter, the U200 can fit into most home decor, making it the perfect addition to any home.
The Aqara Smart Lock U200 is now available for pre-order on Kickstarter at https://www.kickstarter.com/projects/aqara-u200/smartlock for those looking to be among the first to explore the latest in home access technologies.
- The U200 can be paired to the Aqara Home app using Bluetooth or the upcoming Aqara Hub M3. Compatibility with third-party Matter-enabled platforms (e.g., Amazon Alexa, Apple Home, Google Home, Samsung SmartThings, Home Assistant) is expected to roll out in waves, and may not be available by the shipment of pre-ordered units.
- HomeKey unlocking support is currently under development, and is expected to become available via a subsequent OTA update after the lock receives certain certification.
- Limitation applies. Please check the Kickstarter page or consult Aqara support for detailed guidelines on the U200 lock compatibility.
- The 6-month battery life is based on the assumption of 8 cycles of fingerprint/NFC unlocking and locking per day.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227373928/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom